Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues. © 2016, International Society of Oncology and BioMarkers (ISOBM).

Treatment of lung large cell neuroendocrine carcinoma / Lo Russo, Giuseppe; Pusceddu, Sara; Proto, Claudia; Macerelli, Marianna; Signorelli, Diego; Vitali, Milena; Ganzinelli, Monica; Gallucci, Rosaria; Zilembo, Nicoletta; Platania, Marco; Buzzoni, Roberto; De Braud, Filippo; Garassino, Marina Chiara. - In: TUMOR BIOLOGY. - ISSN 1010-4283. - 37:6(2016), pp. 7047-7057. [10.1007/s13277-016-5003-4]

Treatment of lung large cell neuroendocrine carcinoma

Lo Russo, Giuseppe
;
2016

Abstract

Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I–II–III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues. © 2016, International Society of Oncology and BioMarkers (ISOBM).
2016
Chemotherapy; Large cell neuroendocrine carcinoma; Lung neuroendocrine tumor; Treatment options; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Humans; Lung Neoplasms; Prognosis; Cancer Research
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Treatment of lung large cell neuroendocrine carcinoma / Lo Russo, Giuseppe; Pusceddu, Sara; Proto, Claudia; Macerelli, Marianna; Signorelli, Diego; Vitali, Milena; Ganzinelli, Monica; Gallucci, Rosaria; Zilembo, Nicoletta; Platania, Marco; Buzzoni, Roberto; De Braud, Filippo; Garassino, Marina Chiara. - In: TUMOR BIOLOGY. - ISSN 1010-4283. - 37:6(2016), pp. 7047-7057. [10.1007/s13277-016-5003-4]
File allegati a questo prodotto
File Dimensione Formato  
Lo-Russo_Treatment_2016.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 401.66 kB
Formato Adobe PDF
401.66 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1018467
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 51
social impact